Related references
Note: Only part of the references are listed.Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene
Yannick Wouters et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes
Juliana Schwaab et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia
Jessica S. Snider et al.
CANCER GENETICS (2020)
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes. Version 3.2021
Aaron T. Gerds et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Myeloid neoplasm with eosinophilia and PCM1-JAK2 associated with acute promyelocytic leukemia with PML-RARA
Sajad Salehi et al.
LEUKEMIA & LYMPHOMA (2019)
World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management
William Shomali et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study
Guilin Tang et al.
MODERN PATHOLOGY (2019)
Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2
Constance Baer et al.
HAEMATOLOGICA (2018)
PCM1-JAK2 Fusion in a Patient With Acute Myeloid Leukemia
Jong-Mi Lee et al.
ANNALS OF LABORATORY MEDICINE (2018)
Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2
Constance Baer et al.
HAEMATOLOGICA (2018)
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase
Mohamad Jawhar et al.
ANNALS OF HEMATOLOGY (2017)
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
Alessandro Maria Vannucchi et al.
ANNALS OF HEMATOLOGY (2017)
Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies
Katrien Van Roosbroeck et al.
GENES CHROMOSOMES & CANCER (2016)
A t(8;9)(p22;p24)/PCM1-JAK2 Translocation in a Patient With Myeloproliferative Neoplasm and Myeloid Sarcoma: First Report in Korea
Ilgeun Song et al.
ANNALS OF LABORATORY MEDICINE (2016)
Hematolymphoid Neoplasms Associated With Rearrangements of PDGFRA, PDGFRB, and FGFR1
Francisco Vega et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene
Elisa Rumi et al.
ANNALS OF HEMATOLOGY (2015)
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib
Chan Y. Cheah et al.
BLOOD (2014)
Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?
Barbara J. Bain et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1
Verena Patterer et al.
ANNALS OF HEMATOLOGY (2013)
A myeloproliferative neoplasm with translocation t(8;9)(p22;p24) involving JAK2 gene
Nakhle Saba et al.
BLOOD (2013)
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Srdan Verstovsek et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Implication of MAPK1/MAPK3 signalling pathway in t(8;9)(p22;24)/PCM1-JAK2 myelodysplastic/myeloproliferative neoplasms
Elena Masselli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements
Andrew Chase et al.
HAEMATOLOGICA (2013)
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase
G. Metzgeroth et al.
LEUKEMIA (2013)
The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia New Insights Based on a Survey of 44 Cases
Fanny Legrand et al.
MEDICINE (2013)
Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue
Silvia Salmoiraghi et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia
Els Lierman et al.
BLOOD (2012)
Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome
A. Pardanani et al.
LEUKEMIA (2012)
Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?
Monika Prochorec-Sobieszek et al.
LEUKEMIA & LYMPHOMA (2012)
Association of JAK2 Mutation Status and Cytogenetic Abnormalities in Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms
Jennifer Dunlap et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma
Katrien Van Roosbroeck et al.
BLOOD (2011)
Pathology of the bone marrow and spleen in a case of myelodysplastic/myeloproliferative neoplasm associated with t(8;9)(p22;p24) involving PCM1 and JAK2 genes
Jean-Louis Dargent et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates
Mrinal M. Patnaik et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders
Ana L. Basquiera et al.
HEMATOLOGY (2009)
A third case of chronic eosinophilic leukemia with the (8;9)(p23;p24) translocation
Dennis B. Cornfield et al.
CANCER GENETICS AND CYTOGENETICS (2008)
Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia
Kuan-Po Huang et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma
J Adélaïde et al.
LEUKEMIA (2006)
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene
M Bousquet et al.
ONCOGENE (2005)
Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case
S Heiss et al.
HUMAN PATHOLOGY (2005)
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes
DP Steensma et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
A Reiter et al.
CANCER RESEARCH (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation
A Murati et al.
LEUKEMIA (2005)
Share Paper
